Sanofi $SNY Shares Sold by Ethic Inc.

Key Points

• Ethic Inc. reduced its stake in Sanofi by 18.9% in the second quarter, ending with 108,424 shares valued at approximately $5.19 million.
• Sanofi's stock recently opened at $49.52, with a market cap of $121.60 billion and a PE ratio of 11.90, showing a year-over-year revenue decline of 7%.
• Analysts have mixed views on Sanofi, with the stock receiving ratings ranging from Strong Buy to Hold, and an average price target of $62.67.

Ethic Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 18.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,424 shares of the company's stock after selling 25,348 shares during the period. Ethic Inc.'s holdings in Sanofi were worth $5,188,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the period. GAMMA Investing LLC lifted its position in shares of Sanofi by 58.7% in the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company's stock valued at $336,000 after acquiring an additional 2,241 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Sanofi by 1.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company's stock valued at $1,848,000 after acquiring an additional 318 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Sanofi by 3.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 8,640 shares of the company's stock valued at $479,000 after acquiring an additional 298 shares in the last quarter. Finally, Golden State Equity Partners purchased a new stake in shares of Sanofi in the 1st quarter valued at approximately $246,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Down 0.9%

Sanofi stock opened at $49.52 on Friday. The firm has a market cap of $121.60 billion, a PE ratio of 11.90, a P/E/G ratio of 1.21 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm's 50 day moving average price is $48.61 and its two-hundred day moving average price is $49.54. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.73 earnings per share. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Weiss Ratings restated a "hold (c)" rating on shares of Sanofi in a research report on Wednesday, October 8th. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.